[1]滕悦魏艳陈英耀严俊涛刘柳李福明.中药注射剂抗肿瘤治疗的医患偏好及共同决策比较分析[J].中国卫生质量管理,2023,30(02):60-64.[doi:10.13912/j.cnki.chqm.2023.30.2.14 ]
 TENG Yue,WEI Yan,CHEN Yingyao.Comparative Analysis of Physicians' and Patients' Preference and Shared Decision Making of TCM Injection in Anti-tumor Therapy[J].Chinese Health Quality Management,2023,30(02):60-64.[doi:10.13912/j.cnki.chqm.2023.30.2.14 ]
点击复制

中药注射剂抗肿瘤治疗的医患偏好及共同决策比较分析

参考文献/References:

[1]赖桂花,王 菲,周 芳,等.差异视角下中西医治疗肿瘤的协同优势[J].中医药临床杂志,2022,34(4):599-603. [2]董子洵,冯佳佳,常佳慧,等.中药注射剂在肿瘤领域的应用研究[J].中国研究型医院,2019,6(5):14-22. [3]荣红国,董 玥,于蔚洁,等.政策工具视角下我国中药注射剂发展政策研究[J].中国药房,2022,33(8):917-922. [4]陈诗琪,郑 蕊,李幼平,等.中药注射剂临床应用存在问题及说明书的相关思考与建议[J].世界科学技术-中医药现代化,2018,20(10):1718-1722. [5]杜治政.共同决策:弥合分歧,营建医患同心的医疗[J].医学与哲学(A),2018,39(4):1-6. [6]CARMAN KL, DARDESS P, MAURER M, et al. Patient and family engagement: a framework for understanding the elements and developing interventions and policies[J]. Health Aff (Millwood),2013,32(2):223-231. [7]COULTER A, ELLINS J. Effectiveness of strategies for informing, educating, and involving patients[J]. BMJ,2007,335(7609):24-27. [8]CHARMEL PA, FRAMPTON SB. Building the business case for patient-centered care[J]. Healthc Financ Manage,2008,62(3):80-85. [9]明 坚,魏 艳,孙 辉,等.医患共同决策影响因素及对患者结果的影响[J].中国卫生质量管理,2017,24(6):90-93.[10]赵 悦,张培海,沈际勇.医患共享决策模式构建[J].中国卫生质量管理,2022,29(6):55-57,70. [11]LANCSAR E, LOUVIERE J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide[J]. Pharmacoeconomics,2008,26(8):661-677. [12]PEARMAIN D, SWANSON J, KROES E, et al. Stated preference techniques:a guide to practice[M].2nd ed. London:Steer Davies Gleave and Hague Consulting Group Press, 1991:26. [13]杨 鸣. 中药注射剂干预恶性肿瘤循证评价及与化疗药相互作用的评价方法[D].北京:北京中医药大学,2021. [14]孙长河. 中药注射剂联合含铂双药治疗晚期非小细胞肺癌的队列研究[D].北京:北京中医药大学,2021. [15]缪碧芳,阮洪光,曾林淼,等.中药注射剂联合放疗治疗非小细胞肺癌的网状Meta分析[J].中国老年学杂志,2019,39(19):4700-4708. [16]洪晓华,王光耀,刘体勤,等.八种中药注射剂联合紫杉醇和顺铂化疗方案治疗非小细胞肺癌的网状Meta分析[J].中国全科医学,2020,23(26):3311-3323. [17]KRISTON L, SCHOLL I, HLZEL L, et al. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample[J]. Patient Educ Couns,2010,80(1):94-99. [18]SCHOLL I, KRISTON L, DIRMAIER J, et al. Development and psychometric properties of the Shared Decision Making Questionnaire:physician version (SDM-Q-Doc) [J]. Patient Educ Couns,2012,88(2):284-290. [19]DEGNER LF, SLOAN JA, VENKATESH P. The control preferences scale[J]. Can J Nurs Res,1997,29(3):21-43. [20]明 坚,魏 艳,柯 雄,等.药物涂层支架技术临床应用中的患者参与决策研究[J].中国卫生政策研究,2018,11(7):73-77. [21]明 坚,魏 艳,许 艳,等.医学新技术临床应用患者参与决策及其影响因素分析[J].中国医院管理,2018,38(3):15-18. [22]魏 艳.医学新技术转化应用模型构建及实证研究[D].上海:复旦大学,2017. [23]HAUBER B, PENROD JR, GEBBEN D, et al. The value of hope: patients' and physicians' preferences for survival in advanced non-small cell lung cancer[J]. Patient Prefer Adherence,2020,14:2093-2104. [24]袁目北,陈在余.医生诱导需求对我国医疗费用增长的影响[J].中国药物经济学,2020,15(5):30-37,53. [25]STIGGELBOUT AM, PIETERSE AH, DE HAES JC. Shared decision making: concepts, evidence, and practice[J]. Patient Educ Couns,2015,98(10):1172-1179.

更新日期/Last Update: 2023-02-15
版权所有© 2015 《中国卫生质量管理》杂志编辑部
陕ICP备20003462号-1
地 址:西安市友谊西路256号; 邮编:710068 ;电话:029-85214975(传真) 029-85253261转2494
技术支持:西安三才科技实业有限公司 029-88222991